\n<\/p>\n
Printed on Oct 17, 2025<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n Observe us on X @investorideas<\/strong><\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n Contact Investorideas.com\u00a0<\/strong><\/p>\n
<\/p>\n 800-665-0411<\/strong><\/p>\n
Printed on Oct 17, 2025
Share
October 17, 2025 – (Investorideas.com
Newswire), a go-to investing platform overlaying biotech and medtech
shares releases a information and buying and selling alert for Artiva Biotherapeutics,
Inc. (Nasdaq: ARTV), a clinical-stage biotechnology firm whose mission is to […]<\/p>\n","protected":false},"author":1,"featured_media":6222,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.investorideas.com\/images\/investorideas-socialmedia.jpg","fifu_image_alt":"","footnotes":""},"categories":[41],"tags":[3879,3877,2637,1078,2636,3878,977,144,1238],"class_list":["post-6220","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investment","tag-allonk","tag-artv","tag-designation","tag-fast","tag-fda","tag-granted","tag-news","tag-soars","tag-track"],"yoast_head":"\n
\n
\n Share
\n <\/a>
\n<\/section><\/div>\n
\n
<\/p>\n
\n
\n <\/figure>\n
\n
<\/p>\n
\n October 17, 2025 – (Investorideas.com<\/a>
\n Newswire), a go-to investing platform overlaying biotech and medtech
\n shares releases a information and buying and selling alert for Artiva Biotherapeutics,
\n Inc. (Nasdaq: ARTV<\/a>), a clinical-stage biotechnology firm whose mission is to develop
\n efficient, protected, and accessible cell therapies for sufferers with
\n devastating autoimmune illnesses and cancers.
\n <\/p>\n
\n The inventory is buying and selling at $5.69, up 2.92, gaining 105.40% on quantity of
\n over 61 Million shares. The inventory had a morning excessive of $6.19.
\n <\/p>\nInformation abstract:<\/strong><\/h2>\n
\n Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) introduced that the U.S.
\n Meals and Drug Administration (FDA) has granted Quick Observe
\n Designation to its investigational remedy AlloNK\u00ae (AB-101) for
\n treating refractory rheumatoid arthritis (RA) together with
\n rituximab, marking it as the primary drug candidate within the deep B-cell
\n depleting class to obtain this standing for this indication. The
\n firm is prioritizing refractory RA because the lead autoimmune
\n indication for AlloNK, concentrating on over 100,000 underserved U.S.
\n sufferers who stay treatment-refractory regardless of present therapies,
\n with greater than 20 sufferers already handled throughout trials and
\n upcoming information from over 15 refractory RA sufferers, together with a number of
\n with six or extra months of follow-up. Translational information
\n demonstrating uniform deep B-cell depletion and security outcomes
\n highlighting a positive tolerability profile and outpatient-ready
\n routine are anticipated in mid-November, adopted by medical response
\n information within the first half of 2026, with FDA interactions deliberate to
\n probably advance to a pivotal trial. As CEO Fred Aslan, M.D.,
\n said, \u201cWe’re prioritizing refractory RA as our lead
\n autoimmune indication for AlloNK given the dimensions of this underserved
\n inhabitants… [and] may allow AlloNK to turn into the primary deep
\n B-cell depleting remedy to advance to a pivotal trial in sufferers
\n with RA.\u201d<\/em>
\n <\/p>\nInformation:<\/strong><\/h2>\n
\n Artiva introduced that the U.S. Meals and Drug Administration (FDA) has
\n granted Quick Observe Designation to AlloNK\u00ae (often known as AB-101)
\n for the remedy of refractory rheumatoid arthritis (RA) in
\n mixture with rituximab and that the Firm has prioritized
\n refractory RA as this system\u2019s lead indication. AlloNK is
\n believed to characterize the primary drug candidate within the deep B-cell
\n depleting therapeutic class to obtain this designation in
\n refractory RA.
\n <\/p>\n
\n \u201cWe’re prioritizing refractory RA as our lead autoimmune
\n indication for AlloNK given the dimensions of this underserved inhabitants.
\n Regardless of the numerous accredited therapies in RA, there are over 100,000
\n sufferers in the USA who stay remedy refractory and
\n may probably profit from a deep B-cell depleting remedy,\u201d
\n stated Fred Aslan, M.D., Chief Government Officer of Artiva. “We glance
\n ahead to sharing the rising translational and security information in
\n mid-November, supporting AlloNK\u2019s profile as an outpatient-ready
\n remedy able to reaching deep B-cell depletion, adopted by
\n medical response information within the first half of 2026 from greater than 15
\n refractory RA sufferers, a number of of whom may have six or extra months
\n of follow-up. As well as, we’re planning FDA interactions within the
\n first half of 2026 that might allow AlloNK to turn into the primary deep
\n B-cell depleting remedy to advance to a pivotal trial in sufferers
\n with RA.\u201d
\n <\/p>\n
\n AlloNK\u2019s Medical Alternative in RA:<\/strong>
\n <\/h3>\n
\n RA is a power autoimmune illness that impacts over 1.5 million
\n individuals in the USA and may trigger painful joint irritation,
\n progressive joint harm, and incapacity, if not adequately handled.
\n Whereas present remedies akin to methotrexate, TNF inhibitors, and
\n B-cell depleting antibodies have improved outcomes for a lot of sufferers,
\n a major subset turns into refractory and now not responds to or
\n tolerates these choices. These sufferers face ongoing illness exercise,
\n elevated danger of incapacity and joint destruction, and reliance on
\n steroids or immunosuppressants which have long-term toxicity. AlloNK is
\n designed to reinforce the exercise of B-cell-targeting antibodies, such
\n as rituximab, by way of antibody-dependent mobile cytotoxicity. This
\n mechanism of motion is meant to drive deeper and extra sturdy
\n B-cell depletion than antibodies alone, probably enabling long-term
\n sturdy responses.
\n <\/p>\n
\n \u201cI’m inspired by our early information with AlloNK in refractory RA
\n sufferers. Having contributed to the event of main RA
\n therapies together with Humira\u00ae and Orencia\u00ae, I’ve witnessed the
\n unmet want amongst sufferers with refractory RA who proceed to endure
\n from insufficient illness management,\u201d stated Subhashis Banerjee, M.D.,
\n Chief Medical Officer of Artiva. \u201cOf word, most sufferers with RA
\n are handled at group rheumatology clinics reasonably than at giant
\n educational medical facilities. Rising deep B-cell depleting therapies
\n akin to CAR-T and T-cell engagers will be restricted by the necessity for
\n hospitalization or specialised oncology oversight, making them
\n difficult for widespread use. With its infusion-ready, off-the-shelf
\n format, and ease of use just like IV-administered RA medicine, AlloNK in
\n mixture with rituximab has the potential to handle this unmet
\n want in a scalable and broadly accessible approach.\u201d
\n <\/p>\nKey Highlights:<\/strong><\/h3>\n
\n Firm is prioritizing refractory RA as its lead indication,
\n reflecting the chance to handle this unmet want with a
\n probably impactful remedy that may be administered and managed in
\n the group setting
\n <\/p>\n
\n Acquired FDA Quick Observe Designation for AlloNK in refractory RA,
\n representing the primary recognized drug candidate within the deep B-cell
\n depleting therapeutic class to obtain this designation in RA
\n <\/p>\n
\n Greater than 20 sufferers handled with AlloNK + mAb throughout refractory RA,
\n Sj\u00f6gren\u2019s illness, systemic lupus erythematosus, lupus
\n nephritis, and systemic sclerosis in company-sponsored trials and an
\n investigator-initiated basket trial, at 1 billion and 4 billion cells
\n per AlloNK dose
\n <\/p>\n
\n Rising translational and security information anticipated to assist
\n AlloNK\u2019s profile as an outpatient-ready remedy able to
\n reaching constant and deep B-cell depletion
\n <\/p>\n
\n Relying on our regulatory interactions with the FDA, AlloNK has the
\n potential to turn into the primary remedy inside the rising deep B-cell
\n depletion class, which incorporates auto-CAR-T and T-cell engagers, to
\n advance to a pivotal trial for sufferers with refractory RA
\n <\/p>\n
\n Full information
\n https:\/\/finance.yahoo.com\/information\/artiva-biotherapeutics-announces-refractory-rheumatoid-200500522.html<\/a>
\n <\/p>\n
\n
<\/p>\n
\n Analysis biotech and medical gadget\/ tech shares at
\n Investorideas.com\u00a0<\/strong>
\n <\/p>\n
\n https:\/\/www.investorideas.com\/BIS\/<\/a><\/strong>
\n <\/p>\n
\n
<\/p>\n
\n About Investorideas.com – Huge Investing Concepts<\/strong>
\n <\/h3>\n
\n Investorideas.com is the go-to platform for giant investing concepts. From
\n breaking inventory information to top-rated investing podcasts, we cowl all of it
\n <\/p>\n
\n Observe us on Fb
\n https:\/\/www.fb.com\/Investorideas<\/a><\/strong>
\n <\/p>\n
\n Observe us on YouTube
\n https:\/\/www.youtube.com\/c\/Investorideas<\/a><\/strong>
\n <\/p>\n
\n
\n <\/div>\n
\n Disclaimer\/Disclosure:<\/strong> Our web site doesn’t make
\n suggestions for purchases or sale of shares, companies or merchandise.
\n This isn’t funding opinion: Nothing on our websites must be construed
\n as a proposal or solicitation to purchase or promote merchandise or securities. All
\n investing entails danger and attainable losses. Extra disclaimer data:
\n https:\/\/www.investorideas.com\/About\/Disclaimer.asp<\/a>
\n Study extra about publishing your information launch and our different information
\n companies and costs on the Investorideas.com newswire
\n https:\/\/www.investorideas.com\/Information-Add\/<\/a>
\n World traders should adhere to rules of every nation. Please learn
\n Investorideas.com privateness coverage:
\n https:\/\/www.investorideas.com\/About\/Private_Policy.asp<\/a>
\n <\/p>\n\n","protected":false},"excerpt":{"rendered":"